» Articles » PMID: 34064375

Pathophysiology and Treatment Options for Hepatic Fibrosis: Can It Be Completely Cured?

Overview
Journal Cells
Publisher MDPI
Date 2021 Jun 2
PMID 34064375
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatic fibrosis is a dynamic process that occurs as a wound healing response against liver injury. During fibrosis, crosstalk between parenchymal and non-parenchymal cells, activation of different immune cells and signaling pathways, as well as a release of several inflammatory mediators take place, resulting in inflammation. Excessive inflammation drives hepatic stellate cell (HSC) activation, which then encounters various morphological and functional changes before transforming into proliferative and extracellular matrix (ECM)-producing myofibroblasts. Finally, enormous ECM accumulation interferes with hepatic function and leads to liver failure. To overcome this condition, several therapeutic approaches have been developed to inhibit inflammatory responses, HSC proliferation and activation. Preclinical studies also suggest several targets for the development of anti-fibrotic therapies; however, very few advanced to clinical trials. The pathophysiology of hepatic fibrosis is extremely complex and requires comprehensive understanding to identify effective therapeutic targets; therefore, in this review, we focus on the various cellular and molecular mechanisms associated with the pathophysiology of hepatic fibrosis and discuss potential strategies to control or reverse the fibrosis.

Citing Articles

miR-372-3p represses hepatic stellate cell activation via the RhoC/ROCK pathway.

Ou S, Tang X, Li Z, Ouyang R, Lei Y, Chen G Cytotechnology. 2025; 77(2):60.

PMID: 39959789 PMC: 11828770. DOI: 10.1007/s10616-025-00715-9.


Focal adhesion kinase promotes aerobic glycolysis in hepatic stellate cells via the cyclin D1/c-Myc/MCT-1 pathway to induce liver fibrosis.

Huang T, Zhou M, Zou G, Hu R, Han L, Zhang Q Sci Rep. 2025; 15(1):4552.

PMID: 39915293 PMC: 11802747. DOI: 10.1038/s41598-025-88538-8.


Cutting-edge insights into liver fibrosis: advanced therapeutic strategies and future perspectives using engineered mesenchymal stem cell-derived exosomes.

Didamoony M, Soubh A, Ahmed L Drug Deliv Transl Res. 2025; .

PMID: 39853531 DOI: 10.1007/s13346-024-01784-7.


Pharmacotherapy of Liver Fibrosis and Hepatitis: Recent Advances.

Zhao L, Tang H, Cheng Z Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770566 PMC: 11677259. DOI: 10.3390/ph17121724.


Molecular mechanisms behind the inhibitory effects of ginsenoside Rg3 on hepatic fibrosis: a review.

Tian Z, Hu R, Wang Z, Wang Y, Li W Arch Toxicol. 2024; 99(2):541-561.

PMID: 39729114 DOI: 10.1007/s00204-024-03941-w.


References
1.
Li L, Shan S, Kang K, Zhang C, Kou R, Song F . The cross-talk of NLRP3 inflammasome activation and necroptotic hepatocyte death in acetaminophen-induced mice acute liver injury. Hum Exp Toxicol. 2020; 40(4):673-684. DOI: 10.1177/0960327120961158. View

2.
Giugliano S, Kriss M, Golden-Mason L, Dobrinskikh E, Stone A, Soto-Gutierrez A . Hepatitis C virus infection induces autocrine interferon signaling by human liver endothelial cells and release of exosomes, which inhibits viral replication. Gastroenterology. 2014; 148(2):392-402.e13. PMC: 4765499. DOI: 10.1053/j.gastro.2014.10.040. View

3.
Chen L, Chen R, Velazquez V, Brigstock D . Fibrogenic Signaling Is Suppressed in Hepatic Stellate Cells through Targeting of Connective Tissue Growth Factor (CCN2) by Cellular or Exosomal MicroRNA-199a-5p. Am J Pathol. 2016; 186(11):2921-2933. PMC: 5222964. DOI: 10.1016/j.ajpath.2016.07.011. View

4.
Dewidar B, Meyer C, Dooley S, Meindl-Beinker A . TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019. Cells. 2019; 8(11). PMC: 6912224. DOI: 10.3390/cells8111419. View

5.
Chang Y, Li H . Hepatic Antifibrotic Pharmacotherapy: Are We Approaching Success?. J Clin Transl Hepatol. 2020; 8(2):222-229. PMC: 7438353. DOI: 10.14218/JCTH.2020.00026. View